Similarly, studies in breast tumor xenografts generated by ErbB-2 positive BTA474 breast cancer cells suggested that the combination of trastuzumab with GSI could decrease the recurrence of ErbB-2-positive breast tumors and may be beneficial in the treatment of recurrent trastuzumab-resistant disease [216]. Here, ERBB2 is linked to breast carcinoma.